Molecular Partners AG Sustainability Reports
Molecular Partners AG is a clinical-stage biopharmaceutical company that pioneers the development of DARPin therapeutics, a novel class of custom-built protein drugs. Its primary pipeline focus areas address medical challenges in oncology and targeted radiopharmaceuticals that conventional treatment modalities cannot easily target.
Sector: Professional & technical services
Country: Switzerland
Exchange: SIX Swiss Exchange
LEI: 875500AXMLDAZ4D21744
FIGI: BBG001T7D8K6
2 reports from 2024 to 2025
